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ABSTRACT Issues regarding recommendations on empiric antimicrobial therapy for ventilator-
associated pneumonia (VAP) have emerged in specific populations.
To develop and validate a score to guide empiric therapy in brain-injured patients with VAP, we
prospectively followed a cohort of 379 brain-injured patients in five intensive care units. The score was
externally validated in an independent cohort of 252 brain-injured patients and its extrapolation was tested
in 221 burn patients.
The multivariate analysis for predicting resistance (incidence 16.4%) showed two independent factors:
preceding antimicrobial therapy ⩾48 h (p<0.001) and VAP onset ⩾10 days (p<0.001); the area under the
receiver operating characteristic curve (AUC) was 0.822 (95% CI 0.770–0.883) in the learning cohort and
0.805 (95% CI 0.732–0.877) in the validation cohort. The score built from the factors selected in
multivariate analysis predicted resistance with a sensitivity of 83%, a specificity of 71%, a positive
predictive value of 37% and a negative predictive value of 96% in the validation cohort. The AUC of the
multivariate analysis was poor in burn patients (0.671, 95% CI 0.596–0.751).
Limited-spectrum empirical antimicrobial therapy has low risk of failure in brain-injured patients
presenting with VAP before day 10 and when prior antimicrobial therapy lasts <48 h.
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Introduction
Ventilator-associated pneumonia (VAP) is one of the most frequent complications and the main cause of
antibiotics use in intensive care units (ICUs) [1]. Early administration of empiric antibiotic therapy is
recommended because morbidity, mortality and medical costs increase when the treatment is delayed [2].
Given the risk of widespread bacterial resistance associated with unnecessary use of broad-spectrum
antibiotic therapy [3], it is important to balance the individual risk of treatment failure and the
community risk of unnecessary broad-spectrum treatment [4].
In 2005, the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA)
recommended restricting the use of broad-spectrum antibiotics to patients with a high risk of
drug-resistant pathogens, i.e. with one or more risk factors: immune suppression, healthcare-associated
pneumonia, antimicrobial therapy in the preceding 3 months and current hospitalisation of ⩾5 days [5].
However, unjustified broad-spectrum empirical therapy is still common in Europe [6] and issues regarding
the validity of these recommendations have emerged. Notably, the strict application of the ATS/IDSA
criteria to unselected ICU populations considered at risk of resistance has been associated with an
increased rate of death [7].
We and others have previously proposed that some specific conditions, such as trauma, are associated with
a low risk of drug-resistant bacteria [8, 9]. The rate of VAP reaches up to 40% for brain-injured patients
hospitalised in ICUs [10–12]. An optimisation of the current practice for antimicrobial therapy in this
population could therefore have a significant impact. The main objective of this study was to develop and
validate a bedside scoring system to predict resistance to antimicrobial therapy in brain-injured patients
presenting with VAP. The second objective was to confirm that the initial condition on ICU admission
significantly alters the risk of resistance of bacteria involved in VAP and we thus evaluated this using the
simplified bedside scoring system in an extrapolation cohort of severe burn patients.
Methods
Study design and setting
From January 2007 to March 2013, a prospective, observational, multicenter study was conducted in five
ICUs of three university hospitals from the ATLANREA study group, in France. This report follows the
STROBE statement for observational studies [13].
Ethics and consent
The local ethics committee of the University Hospital of Nantes approved the study protocol (Groupe
Nantais d’Ethique dans le Domaine de la Santé, Nantes, France). The need for written consent was waived
in this epidemiological study because of its observational design. The study was performed in accordance
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Learning and validation cohorts: brain-injured patients
Brain-injured patients developing an episode of VAP were included in the participating ICUs. Brain injury
was considered as a Glasgow Coma Scale score ⩽12 associated with an anomaly related to an acute
process on a brain computed tomography (CT) scan [11]. Comatose patients with a normal brain CT scan
were not included.
Extrapolation cohort: severe burn patients
Patients with a burn size ⩾10% of the total cutaneous surface developing an episode of VAP were
recruited in a specialised burn ICU admitting all severe burn patients in the geographic area of the five
participating ICUs [14].
Exclusion criteria
Exclusion criteria were age younger than 18 years or refusal to participate after information was provided.
Definition of ventilator-associated pneumonia
The definition of VAP followed the international guidelines [5, 15]. Pneumonia was considered when at
least two signs (body temperature >38°C; leukocytosis >12000 mL–1 or leukopenia <4000 mL–1; purulent
pulmonary secretions, increase in daily minimum inspiratory oxygen fraction of ⩾10%) were associated
with the appearance of a new infiltrate or changes in an existing infiltrate on chest radiograph. Respiratory
tract samples using a quantitative culture (threshold of 104 CFU·mL–1) for a bronchoalveolar lavage,
103 CFU·mL–1 for a nonbronchoscopic sample or protected specimen brush and 106 CFU·mL–1 for a
tracheal sample) were harvested before modification or introduction of any new antimicrobial therapy.
Only episodes with positive cultures were counted as VAP. VAP was defined as pneumonia developing
after 48 h of mechanical ventilation and no later than 48 h following extubation.
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Significant healthcare in the previous 90 days was considered in the case of hospitalisation for ⩾2 days in
the preceding 90 days, or residence in a nursing home or extended care facility, home infusion therapy
including antibiotics, home wound care or chronic dialysis within 30 days [16, 17].
Definition of resistance to limited-spectrum antimicrobial therapy
Limited-spectrum antimicrobial therapy was defined by the ATS/IDSA as the use of ampicillin/sulbactam,
ceftriaxone or levofloxacin [5]. Resistance to limited-spectrum antimicrobial therapy was considered when a
bacterial strain was resistant to one or more of these antibiotics. In VAP involving at least two strains,
resistance was considered as soon as one bacteria was not susceptible to limited-spectrum antimicrobial
therapy. Antimicrobial resistance was defined according to the European Committee on Antimicrobial
Susceptibility Testing for all the bacteria with a load higher than a pre-specified threshold. Following ATS/
IDSA guidelines [5], Serratia marcescens and Enterobacter species with low minimal inhibitory concentrations
for ampicillin/sulbactam, ceftriaxone and levofloxacin (⩽4, ⩽1 and ⩽2 mg·mL−1, respectively) were considered
susceptible to treatment with narrow-spectrum antimicrobial therapy.
Inappropriate empirical therapy was considered when at least one bacteria was resistant to the empirical
treatment.
Preventive strategies for VAP
All the participating ICUs routinely applied the following care to prevent VAP: selective oropharyngeal
antiseptic decontamination, monitoring of the tracheal cuff pressure, semirecumbent positioning and early
enteral feeding. Early tracheotomy, subglottic secretion drainage and selective digestive decontamination
were not used. Following French recommendations, antibiotic prophylaxis (⩽2 days) was used in the case
of surgery and/or contaminated wounds.
Data collection
Demographic data, clinical parameters at VAP onset and outcomes were prospectively collected during
ICU hospitalisation. The first episode of VAP was the only one considered in patients presenting with
multiple infections during ICU hospitalisation.
Statistical analysis
60% of brain-injured patients were randomly assigned to a learning cohort and 40% were assigned to a
validation cohort. This random assignment allowed us to assess the stability and the robustness of results
in the validation cohort without any a priori knowledge of the allocation of patients to one cohort or
another [18].
First, we identified potential risks factors in the learning cohort by univariate analysis with a cut-off point
at 0.20 for the p-value. Criteria collected after VAP diagnosis (e.g. total duration of mechanical ventilation
or of hospitalisation, death) were not considered relevant to help clinicians to select a priori an optimal
antimicrobial therapy and thus were not included in the multivariate analysis. Second, receiver operating
characteristic (ROC) curves were constructed to determine the best cut-offs for quantitative factors selected
by the univariate analysis (duration of antimicrobial therapy prior to VAP onset, time between
hospitalisation and VAP onset). Statistical indices corresponding to each possible value and clinical
considerations (use of discontinuous rather than continuous variables) were taken into account for
simplified clinical application and efficiency. Third, variables identified as potential risk factors in
univariate analyses were included in a multivariate logistic model in which a backward selection was
subsequently applied. Fourth, to validate this predictive model: 1) internal validity was estimated in the
learning cohort, 2) reproducibility was estimated in the validation cohort (external validity) and 3)
transportability was estimated in the extrapolation cohort of burn patients (external validity).
Discrimination was evaluated using the area under the ROC curve (AUC) and its 95% confidence interval,
and calibration was assessed using the Hosmer–Lemeshow test. Finally, an easy-to-use score was
constructed with the variables identified in the predictive model (which was similar for the learning and
validation cohorts). We considered that patients with no risk factor as at low risk of drug-resistant bacteria
and other patients at high risk. The discriminative ability of the simplified score (sensitivity, specificity,
positive predictive value and negative predictive value) was estimated in the three cohorts to externally
validate the simplified score.
Continuous variables were expressed as median (interquartile range (IQR)) for nonparametric data or mean
±SD for parametric data. Qualitative variables were expressed as n (%). The significance level was set at
p⩽0.05. Analyses were performed with SAS statistical software version 9.3 (SAS Institute, Cary, NC, USA).
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Results
Brain-injured populations
During the study period, 631 brain-injured patients were included (379 in the learning cohort, 252 in the
validation cohort; figure 1). The distribution of the bacteria responsible for VAP is described in the
table 1. In the learning and validation cohorts, 62 (16.4%) and 42 (16.7%) patients, respectively, presented
with resistant bacteria to limited-spectrum antimicrobial therapy. Out of the 631 brain-injured patients,
34 (5.4%) received inappropriate empirical therapy. Inappropriate empirical therapy was not associated
with an increased duration of mechanical ventilation (p=0.46) and had no significant effect on the rate of
mortality (p=0.81) (table 2).
Univariate analysis: selection of the potential risk factors associated with resistance
The demographic characteristics and the clinical findings at the time of VAP diagnosis are described in
tables 3 and 4, respectively. The rate of significant healthcare in the previous 90 days and the criteria used
for the diagnosis of VAP (white blood cell number, arterial oxygen tension/inspiratory oxygen fraction
ratio and chest radiograph) did not differ between susceptible and resistant bacteria, and were thus not
included in the multivariate analysis. In the univariate analysis, the factors potentially associated with drug
resistance were: neurosurgery prior to ICU admission (p=0.02), mechanical ventilation on admission
(p=0.11), body temperature (p=0.08), duration of antimicrobial administration prior to VAP diagnosis
(including prophylaxis and/or curative treatment, p<0.001), and median time between hospitalisation and
VAP onset (p<0.001). These criteria were thus included in the multivariate analysis, which served to build
an easy-to-use score.
Multivariate analysis: independent risk factors for bacteria resistant to limited-spectrum
antimicrobial therapy
In an attempt to simplify the use of the results in clinical practice, the duration of prior antimicrobial
administration and the time between hospitalisation and VAP onset were dichotomised in two categories
(above or below a threshold). The cut-offs of antimicrobial duration during current hospitalisation and of
hospitalisation (48 h and 10 days, respectively) were selected because they provide the best sensitivity/
specificity balance (ROC curves; online supplementary figure S1) and the best calibration of the
multivariate analysis (Hosmer–Lemeshow test p-value >0.05, online supplementary table S1).
The final multivariate analysis selecting the factors independently associated with resistance to
limited-spectrum antimicrobial therapy retained a duration of antimicrobial administration prior to VAP
diagnosis ⩾48 h during current hospitalisation (OR 12.63, 95% CI 6.64–24.03) and a VAP onset ⩾10 days
(OR 2.45, 95% CI 1.23–4.89). The AUC for the prediction of resistance to limited-spectrum antimicrobial
therapy was 0.822 (95% CI 0.770–0.883; Hosmer–Lemeshow test p-value 0.26) versus 0.735 (95% CI
0.697–0.786; Hosmer–Lemeshow test p-value 0.61) when the ATS/IDSA criteria were used for predicting
resistance (online supplementary figure S2).
External validation in brain-injured patients
The multivariate analysis presented good characteristics with high AUC and we thus aimed to test its
robustness in an independent cohort of brain-injured patients. There were no differences in the
characteristics on ICU admission between the learning and the validation cohorts (tables 3 and 4).
In the validation cohort, the AUC for the prediction of resistance was 0.805 (95% CI 0.732–0.877;
Enrolled: brain-injured patients with VAP
n=631
Enrolled: burn patients with VAP
n=221
Extrapolation cohort
n=221
Learning cohort
n=379
Susceptible
n=317 (83.6%)
Resistant
n=62 (16.4%)
Susceptible
n=210 (83.3%)
Resistant
n=42 (16.7%)
Susceptible
n=166 (75.1%)
Resistant
n=55 (24.9%)
Validation cohort
n=252
FIGURE 1 Patient flow diagram. VAP: ventilator-associated pneumonia. Bacteria were defined as resistant or susceptible to limited-spectrum
antimicrobial therapy (ampicillin/sulbactam, ceftriaxone or levofloxacin).
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TABLE 1 Pathogens involved in ventilator-associated pneumonia (VAP) in the brain-injured
population
Learning cohort Validation cohort
Bacteria susceptible to limited-spectrum antimicrobial therapy# 372 267
Meticillin-sensitive Staphylococcus aureus 166 118
Streptococcus pneumoniae 36 15
Haemophilus influenzae 102 61
Escherichia coli 32 30
Enterobacter species¶ 6 12
Klebsiella pneumonia 17 15
Proteus species 5 4
Serratia marcescens¶ 8 2
Others 0 10
Bacteria resistant to limited-spectrum antimicrobial therapy# 84 59
Meticillin-resistant Staphylococcus aureus 12 11
Streptococcus pneumoniae with decreased susceptibility
to penicillin
1 3
Pseudomonas aeruginosa 27 13
Acinetobacter species 3 5
Enteric Gram-negative bacilli with acquired penicillinase+ 17 12
Enteric Gram-negative bacilli with inducible cefalosporinase§ 23 14
Others 1 1
Data are presented as n. #: ampicillin/sulbactam, ceftriaxone or levofloxacin; ¶: according to the American
Thoracic Society/Infectious Diseases Society of America guidelines for VAP [5], Serratia marcescens and
Enterobacter species were considered susceptible to treatment with narrow-spectrum antimicrobial
therapy, except if resistance was found according to European Committee on Antimicrobial Susceptibility
Testing guidelines; +: resulting in resistance to ampicillin/sulbactam; §: Enterobacter cloacae, Citrobacter
freundii, Hafnia alveii and Providencia species.
TABLE 2 Demographical characteristics and outcomes of brain-injured patients with
appropriate or inappropriate empirical antimicrobial therapy for ventilator-associated
pneumonia (VAP)
Appropriate Inappropriate p-value
Subjects 597 34
Age years 48 (31–61) 46.5 (35–62) 0.90
Male 434 (72.7) 23 (67.7) 0.52
Previous hospitalisation in the last 3 months 113 (19.1) 3 (8.8) 0.13
Initial diagnosis 0.36
Traumatic brain injury 329 (55.1) 24 (70.6)
Subarachnoid haemorrhage 143 (24.0) 7 (20.6)
Stroke 73 (12.2) 2 (5.9)
Other 52 (8.7) 1 (2.9)
SAPS-II 40.5 (32–49) 40 (25–49) 0.48
SOFA 8 (6–10) 8.5 (5.5–10) 0.96
Glasgow Coma Scale score on admission 7 (4–9) 8 (4–12) 0.19
Significant healthcare in last 90 days 212 (35.5) 12 (35.3) 0.98
Time between hospitalisation and VAP onset days 7.0±4.8 5.9±3.3 0.08
Time between hospitalisation and VAP onset ⩾10 days yes 127 (21.3) 2 (5.9) 0.03
Antimicrobial administration prior to VAP onset during
current hospitalisation
Yes 367 (61.6) 29 (85.3) <0.01
Duration h 12 (12–72) 48 (24–72) 0.81
Antimicrobial administration prior to VAP onset ⩾48 h yes 143 (24.0) 18 (52.9) <0.001
Duration of mechanical ventilation days 18.3±12.8 20.0±14.4 0.46
Duration of ICU hospitalisation days 25.5±17.5 24.9±15.2 0.86
In ICU death 96 (16.1) 6 (17.7) 0.81
Data are presented as n, median (interquartile range), n (%) or mean±SD, unless otherwise stated. SAPS-II:
new simplified acute physiology score; SOFA: sequential organ failure assessment; ICU: intensive care unit.
DOI: 10.1183/13993003.01314-2015 5
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Hosmer–Lemeshow test p-value 0.49) versus 0.762 (95% CI 0.713–0.825; Hosmer–Lemeshow test p-value
0.93) with the ATS/IDSA guidelines (online supplementary figure S2). The results of the multivariate and
the clinical values of the score in the whole population of 631 brain-injured patients are provided in online
supplementary table S2.
Definition of an easy-to-use score
The robustness of the multivariate analysis prompted us to create a score with the two selected risk factors.
To evaluate the clinical significance of each risk factor taken separately and of their combination, we
investigated the rate of resistance in patients according to the number of risk factors (figure 2). The rates
TABLE 4 Clinical findings at the time of diagnosis of pneumonia in the learning and validation cohorts according to the
presence of bacteria resistant to limited-spectrum antimicrobial therapy#
Learning cohort Validation cohort
Susceptible Resistant p-value Susceptible Resistant p-value
Body temperature °C 38.7±0.8 38.5±0.9 0.08 38.8±0.8 38.9±0.7 0.39
White blood cells ×103 mL–1 12.9±6.1 12.3±5.4 0.56 12.7±6.4 13.1±6.3 0.73
Lobes involved on chest radiograph 1 (1–1) 1 (1–1) 0.39 1 (1–1) 1 (1–1) 0.97
PaO2/FiO2 ratio 186.3±77.7 196.7±92.2 0.44 201.5±86.5 226.7±101.0 0.18
Time between hospitalisation and VAP onset days 6 (4–8) 8.5 (6–11) <0.001 5 (4–8) 11 (7–17) <0.001
Time between hospitalisation and VAP onset ⩾ 10 days yes 48 (15.1) 24 (38.7) <0.001 33 (15.6) 24 (57.1) <0.001
Antimicrobial administration prior to VAP onset during
current hospitalisation
Yes 182 (57.4) 59 (95.2) <0.001 115 (55.0) 40 (95.2) <0.001
Duration h 12 (12–48) 72 (48–120) <0.001 12 (12–48) 54 (18–132) 0.007
Antimicrobial prior to VAP onset ⩾48 h yes 50 (15.8) 45 (72.6) <0.001 39 (18.6) 27 (64.3) <0.001
Data are presented as mean±SD, median (interquartile range) or n (%), unless otherwise stated. PaO2: partial oxygen tension; FiO2: inspiratory
oxygen fraction; VAP: ventilator-associated pneumonia. #: ampicillin/sulbactam, ceftriaxone or levofloxacin.
TABLE 3 Patient characteristics in the learning and validation cohorts according to the presence of bacteria resistant to
limited-spectrum antimicrobial chemotherapy#
Learning cohort Validation cohort
Susceptible Resistant p-value¶ Susceptible Resistant p-value¶
Subjects 317 62 210 42
Age years 49 (31–63) 50 (31–59) 0.93 45 (29–58) 53.5 (38–51) 0.08
Male 225 (71.0) 43 (69.4) 0.80 158 (75.2) 31 (73.8) 0.84
Medical history of corticotherapy 18 (5.7) 2 (3.2) 0.55 9 (4.3) 2 (4.8) 1.00
Immune suppression (active cancer, HIV) 7 (2.2) 1 (1.6) 1.00 4 (1.9) 1 (2.4) 1.00
Previous hospitalisation in last 3 months 64 (20.5) 11 (17.7) 0.63 35 (16.8) 6 (14.3) 0.69
Initial diagnosis 0.45 0.25
Traumatic brain injury 170 (53.6) 39 (62.3) 118 (56.2) 26 (61.9)
Subarachnoid haemorrhage 80 (25.2) 14 (22.6) 50 (23.8) 6 (14.3)
Stroke 40 (12.6) 4 (6.5) 27 (12.9) 4 (9.5)
Other 27 (8.5) 5 (8.1) 15 (7.1) 6 (14.3)
SAPS-II 41 (31–50) 43.5 (28–49) 0.86 40 (33–48) 40 (29–46) 0.82
SOFA 8 (6–10) 8 (6–10) 0.63 8 (6–10) 8 (4.5–10) 0.91
Glasgow Coma Scale score on admission 7 (4–10) 6 (4–10) 0.53 7 (5–9) 7 (6–12) 0.10
Neurosurgery prior to ICU admission 130 (41.0) 16 (25.8) 0.02 79 (37.6) 21 (50.0) 0.13
Mechanical ventilation on admission 303 (95.6) 56 (90.3) 0.11 200 (95.2) 41 (97.6) 0.70
Significant healthcare in last 90 days+ 113 (35.7) 22 (35.5) 0.98 75 (35.7) 14 (33.3) 0.77
Duration of mechanical ventilation days 17.4±11.8 22.1±15.7 0.03 17.8±13.1 23.4±17.8 0.01
Duration of ICU hospitalisation days 23.8±16.1 29.0±17.7 0.02 25.6±18.7 31.3±16.7 0.07
In ICU death 53 (16.7) 8 (12.9) 0.45 37 (17.6) 4 (9.5) 0.19
Data are presented as n, median (interquartile range), n (%) or mean±SD, unless otherwise stated. SAPS-II: new simplified acute physiology score;
SOFA: sequential organ failure assessment; ICU: intensive care unit. #: ampicillin/sulbactam, ceftriaxone or levofloxacin; ¶: p-values for comparison
between susceptible and resistant to limited-spectrum antimicrobial therapy; +: significant healthcare (hospitalisation for ⩾2 days in the preceding
90 days, home wound care or residence in an extended care facility, home infusion therapy including antibiotics, or chronic dialysis within 30 days).
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of bacteria resistant to limited-spectrum antimicrobial therapy was 4.5% in patients with no risk factor and
was significantly higher in patients with one or two risk factors (33–47.4%). The simplified score was
constructed as follows: patients with no factor were considered at low risk of resistant bacteria and patients
with one and/or two factors were considered at high risk. The characteristics of the simplified score are
provided in the table 5. The ability of the score to predict meticillin-resistant Staphylococcus aureus
(MRSA) was lower than for prediction of resistant Gram-negative bacteria (online supplementary table S3).
When compared with the ATS/IDSA criteria, the net reclassification improvement with the simplified
score was 39.1% in the learning cohort and 35.7% in the validation cohort. Among the 252 patients of the
validation cohort, 185 (73.4%) were well classified (true positive or true negative) with the simplified score
versus 82 (32.5%) with the ATS/IDSA criteria (p<0.001). Among the 210 patients free of resistant bacteria,
60 (28.6%) would have received unnecessary broad-spectrum antimicrobial therapy with the simplified
100
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No factor No factorVAP ≥day 10 VAP ≥48 h VAP ≥day 10 
and 
Ab ≥48 h
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n=10 n=7
n=24
n=24
n=45
n=27
n=17 n=16
n=10
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FIGURE 2 Characteristics of the simplified score in the three independent cohorts. Percentage of bacteria
resistant to limited-spectrum antimicrobial therapy in the learning and validation cohorts according to a) the
number of risk factors and b) the simplified score. VAP: ventilator-associated pneumonia; Ab: prior antibiotherapy
administration.
TABLE 5 Clinical performance of the simplified score in predicting bacteria resistant to
limited-spectrum antimicrobial therapy in the learning and the validation cohorts
ATS/IDSA criteria# Simplified score¶
Learning cohort
Sensitivity % 100 84
Specificity % 18 74
Positive predictive value % 19 38
Negative predictive value % 100 96
Positive likelihood ratio 1.2 3.2
Negative likelihood ratio 0.0 0.2
AUC 0.735 0.822
Validation cohort
Sensitivity % 100 83
Specificity % 19 71
Positive predictive value % 20 37
Negative predictive value % 100 96
Positive likelihood ratio 1.2 2.9
Negative likelihood ratio 0.0 0.2
AUC 0.762 0.805
ATS/IDSA: American Thoracic Society/Infectious Diseases Society of America; AUC: area under the receiver
operating characteristic curve. #: in the case of late-onset pneumonia (⩾day 5), previous antimicrobial
therapy in the last 90 days or healthcare-associated pneumonia (hospitalisation for ⩾2 days in the
preceding 90 days, home wound care or residence in an extended care facility, home infusion therapy
including antibiotics, or chronic dialysis within 30 days); ¶: in the case of late-onset pneumonia (⩾day 10) or
of previous antimicrobial administration ⩾48 h.
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score (false positive, wrongfully classified as resistant) as compared with 170 (81.0%) with the ATS/IDSA
criteria (p<0.001).
Extrapolation to burn patients
Finally, to examine if the simplified score could be extrapolated to other ICU populations or should be used
only in brain-injured patients, we assessed its predictive values in severe burn patients. Since burn patients
were from the same geographic area and from the same hospitals, we considered that any potential
differences could not be explained by local variation in ecology [19], but rather by the acute condition on
admission (burn versus brain injury). The demographic characteristics and pathogens involved in the
cohort of severe burn patients are provided in online supplementary tables S4 and S5. Of 221 patients
presenting with VAP, 55 (24.9%) had bacteria resistant to limited-spectrum antimicrobial therapy as
compared with 16.7% in the validation cohort of brain-injured patients (p=0.03). The AUC of the
simplified score was 0.671 (95% CI 0.596–0.751) in the burn patients versus 0.805 (95% CI 0.732–0.877) in
the brain-injured patients of the validation cohort (online supplementary figure S2). The sensitivity and the
specificity values of the simplified score were low in burn patients (69% and 60%, respectively).
Discussion
In this study we developed and externally validated a clinical score for the prediction of resistance to
limited-spectrum antimicrobial therapy in brain-injured patients presenting with VAP. We show that
resistant bacteria should be considered when at least one of the two following factors are present: prior
antimicrobial administration during current hospitalisation ⩾48 h and/or VAP occurrence ⩾10 days after
ICU admission. Brain-injured patients with none of these criteria have a low probability of VAP caused by
resistant bacteria. Importantly, this score seems to be specific to brain-injured patients, since it cannot be
extrapolated to burn patients.
A restrictive approach to broad-spectrum empiric antimicrobial therapy for VAP could theoretically be
advocated in circumstances with a low rate of resistance because the rate of patients wrongfully considered
with susceptible bacteria (false negative) will be low. Hence, the intermediate rate of resistance in the
participating hospitals (incidence per 1000 patient days: 0.2–0.6 for MRSA and 0.2–0.4 for
extended-spectrum β-lactamase [20]) probably contributed to the high negative predictive value of the
score (96%). However, low rate rates of resistance have already been reported in trauma patients
independently from the rate of resistance in the community [9]. Accordingly, the rate of resistance was
lower in brain-injured patients than in burn patients in the current study. Taken together, these results
argue that the rates of resistance of pathogens involved in VAP are lower in brain-injured patients than in
other ICU populations and this result is independent of the rate of resistance in the community.
According to previous publications, the rate of bacterial resistance to antimicrobial therapy ranged from
10% to 50% (20% on average) [10, 21, 22], which is consistent with our findings. This large range of
resistance rates may be explained by the variations in local ecology [19] and by several definitions of
resistance. Previous predictive scores have been developed considering the natural susceptibility of species
to antibiotics, but not the acquired nonnatural resistance (e.g. extended-spectrum β-lactamase) despite the
fact that an increasing frequency is observed in the community [23]. The current definition, based on the
measured susceptibility to commonly used antibiotics, could be more useful in clinical practice.
As previously described [24], prior antimicrobial administration and the duration of ICU hospitalisation
before VAP were associated with resistance, but we significantly altered the respective thresholds described
in the current guidelines [5]. Our results can significantly alter clinical practice, notably in surgical ICUs.
Indeed, short-course antimicrobial treatment that efficiently prevents surgical infection or VAP [25, 26]
can thus be considered at low risk when using the score described here. The 48-h cut-off, which is in line
with the demonstration that a 3-day regimen of antimicrobial agents increases the rate of resistance [3],
prompted clinicians to limit prophylaxis to a maximal duration of 48 h.
Contrary to previous publications and recommendations [5, 17], we found no association between
resistance and significant healthcare (such as previous hospitalisation) in the last 3 months. In a recent
large study in Spain, the empirical antimicrobial therapy recommended for community-acquired
pneumonia (limited-spectrum) was accurate to treat severe healthcare-associated pneumonia, defined as
developing in patients with one of these two risk factors [22]. Moreover, healthcare-associated pneumonia
was not associated with resistance of Pseudomonas aeruginosa in ICU patients with VAP [27]. These
results suggest that healthcare-associated risk factors should be better defined before any definitive
conclusion can be drawn [28]. Notably, colonisation with antimicrobial-resistant bacteria seems to rapidly
decrease after hospital discharge, reaching <50% after 2 months [29]. Thus, the delay to consider a
preceding hospitalisation (90 days) as a risk factor of bacterial resistance could possibly be reduced in
brain-injured patients.
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The use of the simplified score to guide the initial probabilistic antibiotic therapy could increase the
number of patients that may receive limited-spectrum pre-emptive antimicrobial therapy. Only 4% of
patients were mistakenly considered at low risk (false negative, risk of treatment failure) with the simplified
score, while the rate of patients receiving unnecessary broad-spectrum antimicrobial therapy (false positive)
decreased from 81% with the ATS/IDSA criteria down to 28.6% with the simplified score. This decreased
rate of unnecessary broad-spectrum antimicrobial therapy could bring some favourable effects: 1) for the
community, because it could theoretically decrease the selection of resistant bacteria in the ICU [30], and 2)
for each patient, because the use of unnecessary broad-spectrum antimicrobial therapy has been associated
with infection relapse in populations with a high rate of meticillin-susceptible S. aureus [31].
The accuracy of the simplified score was poor in burn patients, in which the rate of resistance was higher
than in brain-injured patients (24.9% versus 16.7%, respectively). As the burn and the brain-injured
patients were recruited in the same geographical area, the reported differences should not be explained by
variations in the local ecology. Demographic data and medical history of brain-injured and burn cohorts
were similar (tables 1 and 2, and online supplementary table S3), suggesting that the observed differences
in the rate of resistance depend on the condition on admission. Accordingly, the diagnosis on admission
has been shown to impact the epidemiology of VAP in a mixed ICU [8]. We thus propose to consider the
initial condition (brain injury versus other conditions) when prescribing empirical antimicrobial therapy
for VAP. The simplified score can be deemed adequate for brain-injured patients, but the ATS/IDSA
criteria should be used in other conditions.
The study has some limitations. First, we considered only VAP with significant bacterial growth. The
simplified score needs to be validated in VAP with low bacterial burden. Second, the characteristics of the
score were better for the prediction of resistant Gram-negative bacteria than for MRSA. The rate of MRSA
was low in our populations and the predictive values would increase with the prevalence of MRSA in the
population. Third, the definition of limited-spectrum antimicrobial therapy can impact the prognostic
value of the score. Limited-spectrum antimicrobial therapy was defined as the use of ampicillin/sulbactam,
ceftriaxone or levofloxacin because penicillins are the most frequently used antibiotics for treating VAP in
Europe [32], and fluoroquinolones are commonly considered as an alternative to penicillin in case of
allergy and are recommended by the ATS/IDSA [5]. Ertapenem was not considered here because of its
broad spectrum of activity on Enterobacteriaceae and the theoretical risk of resistance associated with the
use of carbapenem. Fourth, one could say that 26.6% of the patients are wrongfully classified, mainly
false-positive diagnoses that could lead to unnecessary broad-spectrum antimicrobial therapy. Since the
empirical therapy usually lasts <3 days, a strategy of de-escalation could limit the risk of spreading
resistance in the community [33]. Fifth, this study was performed in five ICUs from three French hospital
and the generalisability of its results to other geographic areas, notably those with high rates of resistance
in the community, need to be investigated. Finally, this score needs to be validated in a prospective
randomised clinical trial. However, two of the participating ICUs have previously reported an increased
success rate after implementation of such a score in clinical practice [11].
To conclude, we developed and validated an easy-to-use score predicting bacterial resistance to
limited-spectrum antimicrobial therapy in brain-injured patients with VAP. The risk of failure when using
limited-spectrum empirical antibiotic treatment is low if VAP onset before day 10 of hospitalisation and if prior
antimicrobial administration lasts <48 h. As compared with the ATS/IDSA criteria, the simplified score could
significantly decrease the use of unnecessary broad-spectrum antimicrobial therapy in this specific population
and thus limit the spread of antimicrobial resistance. The development of personalised antimicrobial therapy
based on the initial condition, i.e. the use of different pre-emptive antimicrobial therapies in patients with
different diagnosis on admission even if they are exposed to the same bacterial ecology, appears mandatory.
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